$1,318.00
This Market Spotlight report covers the Uterine Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Uterine Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiation therapy
9 Chemotherapy
10 Hormone therapy
10 Immunotherapy
10 Palliative care
11 EPIDEMIOLOGY
15 MARKETED DRUGS
17 PIPELINE DRUGS
23 RECENT EVENTS AND ANALYST OPINION
23 Multiple Drugs for Uterine Cancer (March 19, 2021)
25 KEY UPCOMING EVENTS
26 KEY REGULATORY EVENTS
26 Positive CHMP Opinion For Keytruda Plus Lenvima Combination
26 Keeping Track: Merck & Co. In Spotlight With Keytruda Approval
26 Jemperli Approval Makes Everyone Happy
26 Oncology Accelerated Approval Withdrawals: Which Indications Need Confirmation Next?
27 GSK’s Dostarlimab Gets EU Nod For Endometrial Cancer
28 PROBABILITY OF SUCCESS
29 LICENSING AND ASSET ACQUISITION DEALS
29 BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC
30 REVENUE OPPORTUNITY
31 CLINICAL TRIAL LANDSCAPE
32 Sponsors by status
33 Sponsors by phase
34 Recent events
36 BIBLIOGRAPHY
37 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of uterine cancer, 2019–28
17 Figure 2: Overview of pipeline drugs for uterine cancer in the US
17 Figure 3: Pipeline drugs for uterine cancer, by company
18 Figure 4: Pipeline drugs for uterine cancer, by drug type
18 Figure 5: Pipeline drugs for uterine cancer, by classification
24 Figure 6: Multiple Drugs for Uterine Cancer (March 19, 2021): Phase III – KEYNOTE-775 (w/Pembrolizumab)
25 Figure 7: Key upcoming events in uterine cancer
28 Figure 8: Probability of success in the solid tumors pipeline
31 Figure 9: Clinical trials in uterine cancer
31 Figure 10: Top 10 drugs for clinical trials in uterine cancer
32 Figure 11: Top 10 companies for clinical trials in uterine cancer
32 Figure 12: Trial locations in uterine cancer
33 Figure 13: Uterine cancer trials status
34 Figure 14: Uterine cancer trials sponsors by phase
LIST OF TABLES
12 Table 1: Incident cases of uterine cancer, 2019–28
14 Table 2: Five-year prevalent cases of uterine cancer, 2019–28
16 Table 3: Marketed drugs for uterine cancer
19 Table 4: Pipeline drugs for uterine cancer in the US
23 Table 5: Multiple Drugs for Uterine Cancer (March 19, 2021)
30 Table 6: Historical global sales, by drug ($m), 2016–20
30 Table 7: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!